Subjects -> BIOLOGY (Total: 3134 journals)
    - BIOCHEMISTRY (239 journals)
    - BIOENGINEERING (143 journals)
    - BIOLOGY (1491 journals)
    - BIOPHYSICS (53 journals)
    - BIOTECHNOLOGY (243 journals)
    - BOTANY (220 journals)
    - CYTOLOGY AND HISTOLOGY (32 journals)
    - ENTOMOLOGY (67 journals)
    - GENETICS (152 journals)
    - MICROBIOLOGY (265 journals)
    - MICROSCOPY (13 journals)
    - ORNITHOLOGY (26 journals)
    - PHYSIOLOGY (73 journals)
    - ZOOLOGY (117 journals)

BIOLOGY (1491 journals)                  1 2 3 4 5 6 7 8 | Last

Showing 1 - 200 of 1720 Journals sorted alphabetically
AAPS Journal     Hybrid Journal   (Followers: 31)
Abasyn Journal of Life Sciences     Open Access   (Followers: 3)
ACS Pharmacology & Translational Science     Hybrid Journal   (Followers: 5)
ACS Synthetic Biology     Hybrid Journal   (Followers: 38)
Acta Biologica Hungarica     Full-text available via subscription   (Followers: 5)
Acta Biologica Marisiensis     Open Access   (Followers: 3)
Acta Biologica Sibirica     Open Access   (Followers: 2)
Acta Biologica Turcica     Open Access   (Followers: 1)
Acta Biomaterialia     Hybrid Journal   (Followers: 31)
Acta Biotheoretica     Hybrid Journal   (Followers: 3)
Acta Chiropterologica     Full-text available via subscription   (Followers: 5)
acta ethologica     Hybrid Journal   (Followers: 7)
Acta Fytotechnica et Zootechnica     Open Access   (Followers: 3)
Acta Ichthyologica et Piscatoria     Open Access   (Followers: 5)
Acta Médica Costarricense     Open Access   (Followers: 2)
Acta Musei Silesiae, Scientiae Naturales     Open Access  
Acta Neurobiologiae Experimentalis     Open Access  
Acta Scientiae Biological Research     Open Access   (Followers: 1)
Acta Scientiarum. Biological Sciences     Open Access   (Followers: 2)
Acta Scientifica Naturalis     Open Access   (Followers: 4)
Acta Universitatis Agriculturae et Silviculturae Mendelianae Brunensis     Open Access   (Followers: 2)
Acta Universitatis Lodziensis : Folia Biologica et Oecologica     Open Access  
Actualidades Biológicas     Open Access   (Followers: 1)
Advanced Biology     Hybrid Journal   (Followers: 1)
Advanced Health Care Technologies     Open Access   (Followers: 12)
Advanced Journal of Graduate Research     Open Access   (Followers: 1)
Advanced Membranes     Open Access   (Followers: 5)
Advanced Quantum Technologies     Hybrid Journal   (Followers: 3)
Advances in Bioinformatics     Open Access   (Followers: 22)
Advances in Biological Regulation     Hybrid Journal   (Followers: 4)
Advances in Biology     Open Access   (Followers: 12)
Advances in Biomarker Sciences and Technology     Open Access   (Followers: 3)
Advances in Biosensors and Bioelectronics     Open Access   (Followers: 6)
Advances in Cell Biology/ Medical Journal of Cell Biology     Open Access   (Followers: 26)
Advances in Ecological Research     Full-text available via subscription   (Followers: 45)
Advances in Environmental Sciences - International Journal of the Bioflux Society     Open Access   (Followers: 17)
Advances in Enzyme Research     Open Access   (Followers: 10)
Advances in High Energy Physics     Open Access   (Followers: 26)
Advances in Human Biology     Open Access   (Followers: 8)
Advances in Life Science and Technology     Open Access   (Followers: 12)
Advances in Life Sciences     Open Access   (Followers: 5)
Advances in Marine Biology     Full-text available via subscription   (Followers: 29)
Advances in Tropical Biodiversity and Environmental Sciences     Open Access   (Followers: 5)
Advances in Virus Research     Full-text available via subscription   (Followers: 8)
Adversity and Resilience Science : Journal of Research and Practice     Hybrid Journal   (Followers: 3)
African Journal of Ecology     Hybrid Journal   (Followers: 18)
African Journal of Range & Forage Science     Hybrid Journal   (Followers: 12)
AFRREV STECH : An International Journal of Science and Technology     Open Access   (Followers: 3)
Ageing Research Reviews     Hybrid Journal   (Followers: 13)
Aggregate     Open Access   (Followers: 1)
Aging Cell     Open Access   (Followers: 22)
Agrokémia és Talajtan     Full-text available via subscription   (Followers: 2)
AJP Cell Physiology     Hybrid Journal   (Followers: 16)
AJP Endocrinology and Metabolism     Hybrid Journal   (Followers: 26)
AJP Lung Cellular and Molecular Physiology     Hybrid Journal   (Followers: 4)
Al-Kauniyah : Jurnal Biologi     Open Access  
Alasbimn Journal     Open Access   (Followers: 1)
Alces : A Journal Devoted to the Biology and Management of Moose     Open Access  
Alfarama Journal of Basic & Applied Sciences     Open Access   (Followers: 8)
All Life     Open Access   (Followers: 1)
AMB Express     Open Access   (Followers: 1)
Ambix     Hybrid Journal   (Followers: 3)
American Journal of Agricultural and Biological Sciences     Open Access   (Followers: 7)
American Journal of Bioethics     Hybrid Journal   (Followers: 18)
American Journal of Human Biology     Hybrid Journal   (Followers: 17)
American Journal of Medical and Biological Research     Open Access   (Followers: 4)
American Journal of Plant Sciences     Open Access   (Followers: 24)
American Journal of Primatology     Hybrid Journal   (Followers: 17)
American Naturalist     Full-text available via subscription   (Followers: 80)
Amphibia-Reptilia     Hybrid Journal   (Followers: 5)
Anaerobe     Hybrid Journal   (Followers: 3)
Analytical Methods     Hybrid Journal   (Followers: 8)
Analytical Science Advances     Open Access   (Followers: 1)
Anatomia     Open Access   (Followers: 12)
Anatomical Science International     Hybrid Journal   (Followers: 3)
Animal Cells and Systems     Hybrid Journal   (Followers: 5)
Animal Microbiome     Open Access   (Followers: 3)
Animal Models and Experimental Medicine     Open Access  
Annales françaises d'Oto-rhino-laryngologie et de Pathologie Cervico-faciale     Full-text available via subscription   (Followers: 2)
Annales Henri Poincaré     Hybrid Journal   (Followers: 2)
Annales Universitatis Mariae Curie-Sklodowska, sectio C – Biologia     Open Access   (Followers: 1)
Annals of Applied Biology     Hybrid Journal   (Followers: 6)
Annals of Biomedical Engineering     Hybrid Journal   (Followers: 18)
Annals of Human Biology     Hybrid Journal   (Followers: 5)
Annals of Science and Technology     Open Access   (Followers: 2)
Annual Research & Review in Biology     Open Access  
Annual Review of Biomedical Engineering     Full-text available via subscription   (Followers: 18)
Annual Review of Biophysics     Full-text available via subscription   (Followers: 24)
Annual Review of Cancer Biology     Full-text available via subscription   (Followers: 3)
Annual Review of Cell and Developmental Biology     Full-text available via subscription   (Followers: 44)
Annual Review of Food Science and Technology     Full-text available via subscription   (Followers: 13)
Annual Review of Genomics and Human Genetics     Full-text available via subscription   (Followers: 31)
Annual Review of Phytopathology     Full-text available via subscription   (Followers: 11)
Anthropological Review     Open Access   (Followers: 28)
Antibiotics     Open Access   (Followers: 12)
Antioxidants     Open Access   (Followers: 4)
Antioxidants & Redox Signaling     Hybrid Journal   (Followers: 8)
Antonie van Leeuwenhoek     Hybrid Journal   (Followers: 3)
Anzeiger für Schädlingskunde     Hybrid Journal   (Followers: 1)
Apidologie     Hybrid Journal   (Followers: 4)
Apmis     Hybrid Journal   (Followers: 1)
APOPTOSIS     Hybrid Journal   (Followers: 8)
Applied Biology     Open Access  
Applied Bionics and Biomechanics     Open Access   (Followers: 4)
Applied Phycology     Open Access  
Applied Vegetation Science     Full-text available via subscription   (Followers: 9)
Aquaculture Environment Interactions     Open Access   (Followers: 7)
Aquaculture International     Hybrid Journal   (Followers: 25)
Aquaculture Reports     Open Access   (Followers: 3)
Aquaculture, Aquarium, Conservation & Legislation - International Journal of the Bioflux Society     Open Access   (Followers: 9)
Aquatic Biology     Open Access   (Followers: 9)
Aquatic Ecology     Hybrid Journal   (Followers: 42)
Aquatic Ecosystem Health & Management     Hybrid Journal   (Followers: 16)
Aquatic Science and Technology     Open Access   (Followers: 4)
Aquatic Toxicology     Hybrid Journal   (Followers: 26)
Arabian Journal of Scientific Research / المجلة العربية للبحث العلمي     Open Access  
Archaea     Open Access   (Followers: 3)
Archiv für Molluskenkunde: International Journal of Malacology     Full-text available via subscription   (Followers: 1)
Archives of Biological Sciences     Open Access  
Archives of Microbiology     Hybrid Journal   (Followers: 9)
Archives of Natural History     Hybrid Journal   (Followers: 8)
Archives of Oral Biology     Hybrid Journal   (Followers: 2)
Archives of Virology     Hybrid Journal   (Followers: 6)
Archivum Immunologiae et Therapiae Experimentalis     Hybrid Journal   (Followers: 2)
Arctic     Open Access   (Followers: 8)
Arid Ecosystems     Hybrid Journal   (Followers: 2)
Arquivos do Instituto Biológico     Open Access   (Followers: 1)
Arquivos do Museu Dinâmico Interdisciplinar     Open Access  
Arthropod Structure & Development     Hybrid Journal   (Followers: 2)
Arthropod Systematics & Phylogeny     Open Access   (Followers: 3)
Artificial DNA: PNA & XNA     Hybrid Journal   (Followers: 2)
Artificial Intelligence in the Life Sciences     Open Access  
Asian Bioethics Review     Full-text available via subscription   (Followers: 2)
Asian Journal of Biological Sciences     Open Access   (Followers: 2)
Asian Journal of Biology     Open Access  
Asian Journal of Biotechnology and Bioresource Technology     Open Access  
Asian Journal of Cell Biology     Open Access   (Followers: 4)
Asian Journal of Developmental Biology     Open Access   (Followers: 1)
Asian Journal of Medical and Biological Research     Open Access   (Followers: 3)
Asian Journal of Nematology     Open Access   (Followers: 4)
Asian Journal of Poultry Science     Open Access   (Followers: 3)
Atti della Accademia Peloritana dei Pericolanti - Classe di Scienze Medico-Biologiche     Open Access  
Australian Life Scientist     Full-text available via subscription   (Followers: 2)
Australian Mammalogy     Hybrid Journal   (Followers: 8)
Autophagy     Hybrid Journal   (Followers: 8)
Avian Biology Research     Hybrid Journal   (Followers: 4)
Avian Conservation and Ecology     Open Access   (Followers: 17)
Bacterial Empire     Open Access   (Followers: 1)
Bacteriology Journal     Open Access   (Followers: 2)
Bacteriophage     Full-text available via subscription   (Followers: 2)
Bangladesh Journal of Bioethics     Open Access  
Bangladesh Journal of Plant Taxonomy     Open Access  
Bangladesh Journal of Scientific Research     Open Access  
Berita Biologi     Open Access  
Between the Species     Open Access   (Followers: 2)
BIO Web of Conferences     Open Access  
Bio-Grafía. Escritos sobre la Biología y su enseñanza     Open Access  
Bio-Lectura     Open Access  
BIO-SITE : Biologi dan Sains Terapan     Open Access  
Bioactive Compounds in Health and Disease     Open Access  
Biocatalysis and Biotransformation     Hybrid Journal   (Followers: 5)
BioCentury Innovations     Full-text available via subscription   (Followers: 2)
Biochemistry and Cell Biology     Hybrid Journal   (Followers: 18)
Biochimie     Hybrid Journal   (Followers: 4)
BioControl     Hybrid Journal   (Followers: 2)
Biocontrol Science and Technology     Hybrid Journal   (Followers: 5)
Biodemography and Social Biology     Hybrid Journal   (Followers: 1)
BIODIK : Jurnal Ilmiah Pendidikan Biologi     Open Access  
BioDiscovery     Open Access   (Followers: 2)
Biodiversitas : Journal of Biological Diversity     Open Access   (Followers: 2)
Biodiversity : Research and Conservation     Open Access   (Followers: 30)
Biodiversity Data Journal     Open Access   (Followers: 8)
Biodiversity Informatics     Open Access   (Followers: 3)
Biodiversity Information Science and Standards     Open Access   (Followers: 2)
Biodiversity Observations     Open Access   (Followers: 2)
Bioeduca : Journal of Biology Education     Open Access   (Followers: 1)
Bioeduscience     Open Access   (Followers: 2)
Bioeksperimen : Jurnal Penelitian Biologi     Open Access  
Bioelectrochemistry     Hybrid Journal   (Followers: 1)
Bioelectromagnetics     Hybrid Journal   (Followers: 1)
Bioenergy Research     Hybrid Journal   (Followers: 3)
Bioengineering and Bioscience     Open Access   (Followers: 1)
BioEssays     Hybrid Journal   (Followers: 11)
Bioethica     Open Access   (Followers: 1)
Bioethics     Hybrid Journal   (Followers: 21)
BioéthiqueOnline     Open Access   (Followers: 1)
Biogeographia : The Journal of Integrative Biogeography     Open Access   (Followers: 2)
Biogeosciences (BG)     Open Access   (Followers: 17)
Biogeosciences Discussions (BGD)     Open Access   (Followers: 4)
Bioinformatics     Hybrid Journal   (Followers: 283)
Bioinformatics Advances : Journal of the International Society for Computational Biology     Open Access   (Followers: 3)
Bioinformatics and Biology Insights     Open Access   (Followers: 13)
Biointerphases     Open Access   (Followers: 1)
Biojournal of Science and Technology     Open Access  
BioLink : Jurnal Biologi Lingkungan, Industri, Kesehatan     Open Access  
Biologia     Hybrid Journal   (Followers: 1)
Biologia Futura     Hybrid Journal  
Biologia on-line : Revista de divulgació de la Facultat de Biologia     Open Access  
Biological Bulletin     Partially Free   (Followers: 6)
Biological Control     Hybrid Journal   (Followers: 6)

        1 2 3 4 5 6 7 8 | Last

Similar Journals
Journal Cover
BioCentury Innovations
Number of Followers: 2  
 
  Full-text available via subscription Subscription journal
ISSN (Online) 2377-3030
Published by BioCentury Homepage  [1 journal]
  • May 26 Quick Takes: Carmot raises upsized $150M series E

    • Free pre-print version: Loading...

      Abstract: MAY 26, 2023 5:22 PM PDT BIOCENTURY FINANCEMAY 26 QUICK TAKES: CARMOT RAISES UPSIZED $150M SERIES EBY Plus: PFS benefit for Imfinzi, Lynparza in endometrial cancer and updates from TScan and Cedars Sinaihttps://www.biocentury.com/article/648104/may-26-quick-takes-carmot-raises-upsized-150m-series-e© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Fri, 26 May 2023 17:22:46 -070
       
  • TIGIT and LAG3 back in the spotlight at ASCO 2023

    • Free pre-print version: Loading...

      Abstract: MAY 26, 2023 4:52 PM PDT BIOCENTURY PRODUCT DEVELOPMENTTIGIT AND LAG3 BACK IN THE SPOTLIGHT AT ASCO 2023BY Phase I data reignite enthusiasm for checkpoint inhibitors, but will the results reproduce'https://www.biocentury.com/article/648102/tigit-and-lag3-back-in-the-spotlight-at-asco-2023© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Fri, 26 May 2023 16:52:22 -070
       
  • May 26 ASCO Quick Takes: BMS’s Reblozyl headed for SOC in
           first-line MDS

    • Free pre-print version: Loading...

      Abstract: MAY 26, 2023 4:50 PM PDT BIOCENTURY PRODUCT DEVELOPMENTMAY 26 ASCO QUICK TAKES: BMS’S REBLOZYL HEADED FOR SOC IN FIRST-LINE MDSBY Plus: Zentalis’ azenosertib shows early promise in ovarian cancer, and updates from PDS and Elevation https://www.biocentury.com/article/648093/may-26-asco-quick-takes-bms-s-reblozyl-headed-for-soc-in-first-line-mds© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Fri, 26 May 2023 16:50:25 -070
       
  • CHMP seeks to pull Adakveo’s conditional approval; drug has full FDA
           approval

    • Free pre-print version: Loading...

      Abstract: MAY 26, 2023 4:14 PM PDT BIOCENTURY DATA BYTECHMP SEEKS TO PULL ADAKVEO’S CONDITIONAL APPROVAL; DRUG HAS FULL FDA APPROVALBY EMA agency issues positive opinions on Pylclari and Ztalmy, label expansions for Opdivo and Sogroyahttps://www.biocentury.com/article/648099/chmp-seeks-to-pull-adakveo-s-conditional-approval-drug-has-full-fda-approval© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Fri, 26 May 2023 16:14:51 -070
       
  • Wen leaving Invitae as CFO

    • Free pre-print version: Loading...

      Abstract: MAY 26, 2023 4:04 PM PDT BIOCENTURY MANAGEMENT TRACKSWEN LEAVING INVITAE AS CFOBY Plus: Fenton succeeds CEO Requadt at Talaris, and an update from Serahttps://www.biocentury.com/article/648109/wen-leaving-invitae-as-cfo© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Fri, 26 May 2023 16:04:44 -070
       
  • Excision of CGG repeats in fragile X; plus VLP’s saRNA COVID
           vaccine and more

    • Free pre-print version: Loading...

      Abstract: MAY 26, 2023 3:16 PM PDT BIOCENTURY DISCOVERY & TRANSLATIONEXCISION OF CGG REPEATS IN FRAGILE X; PLUS VLP’S SARNA COVID VACCINE AND MOREBY BioCentury’s roundup of translational newshttps://www.biocentury.com/article/648083/excision-of-cgg-repeats-in-fragile-x-plus-vlp-s-sarna-covid-vaccine-and-more© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Fri, 26 May 2023 15:16:25 -070
       
  • U.K. £650M financing package includes major boost for UK Biobank

    • Free pre-print version: Loading...

      Abstract: MAY 26, 2023 3:14 PM PDT BIOCENTURY POLITICS, POLICY & LAWU.K. £650M FINANCING PACKAGE INCLUDES MAJOR BOOST FOR UK BIOBANKBY Financing policies include streamlined trial approvals, investment vehicles for pensionshttps://www.biocentury.com/article/648097/u-k-650m-financing-package-includes-major-boost-for-uk-biobank© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Fri, 26 May 2023 15:14:23 -070
       
  • Three roads to precision neuropsychiatry, says Manji

    • Free pre-print version: Loading...

      Abstract: MAY 26, 2023 3:08 PM PDT BIOCENTURY PRODUCT DEVELOPMENTTHREE ROADS TO PRECISION NEUROPSYCHIATRY, SAYS MANJIBY The U.K. launches its Mental Health Mission, naming former J&J exec Husseini Manji as chairhttps://www.biocentury.com/article/648073/three-roads-to-precision-neuropsychiatry-says-manji© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Fri, 26 May 2023 15:08:29 -070
       
  • BIO seeks clarity, transparency on IRA small biotech exemption

    • Free pre-print version: Loading...

      Abstract: MAY 26, 2023 1:48 PM PDT BIOCENTURY POLITICS, POLICY & LAWBIO SEEKS CLARITY, TRANSPARENCY ON IRA SMALL BIOTECH EXEMPTIONBY Neurocrine and Incyte have said they could qualify for the three-year exemption from price-settinghttps://www.biocentury.com/article/648094/bio-seeks-clarity-transparency-on-ira-small-biotech-exemption© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Fri, 26 May 2023 13:48:58 -070
       
  • May 25 Quick Takes: VarmX is latest biotech to extend series B

    • Free pre-print version: Loading...

      Abstract: MAY 25, 2023 5:56 PM PDT BIOCENTURY FINANCEMAY 25 QUICK TAKES: VARMX IS LATEST BIOTECH TO EXTEND SERIES BBY Plus: Apellis/Sobi candidate misses in ALS and updates from Annexon, Pfizer and morehttps://www.biocentury.com/article/648069/may-25-quick-takes-varmx-is-latest-biotech-to-extend-series-b© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Thu, 25 May 2023 17:56:30 -070
       
  • Chair Thompson to depart Illumina in partial victory for Icahn

    • Free pre-print version: Loading...

      Abstract: MAY 25, 2023 5:12 PM PDT BIOCENTURY MANAGEMENT TRACKSCHAIR THOMPSON TO DEPART ILLUMINA IN PARTIAL VICTORY FOR ICAHNBY Activist investor gains one seat on sequencing company's board. Plus: CEO Clark steps down at Destiny and updates from https://www.biocentury.com/article/648079/chair-thompson-to-depart-illumina-in-partial-victory-for-icahn© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Thu, 25 May 2023 17:12:25 -070
       
  • The 20 biggest venture raises year-to-date: genetic medicines
           dominate 

    • Free pre-print version: Loading...

      Abstract: MAY 25, 2023 5:07 PM PDT BIOCENTURY DATA BYTETHE 20 BIGGEST VENTURE RAISES YEAR-TO-DATE: GENETIC MEDICINES DOMINATE BY Among biotechs that have raised venture rounds of over $100M this year, nearly half are developing genetic medicines https://www.biocentury.com/article/648065/the-20-biggest-venture-raises-year-to-date-genetic-medicines-dominate© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Thu, 25 May 2023 17:07:23 -070
       
  • Alliance advocates for FDA budget 

    • Free pre-print version: Loading...

      Abstract: MAY 25, 2023 4:14 PM PDT BIOCENTURY POLITICS, POLICY & LAWALLIANCE ADVOCATES FOR FDA BUDGET BY Alliance for a Stronger FDA’s Steven Grossman argues Congress must fund agency as a public goodhttps://www.biocentury.com/article/648084/alliance-advocates-for-fda-budget© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Thu, 25 May 2023 16:14:25 -070
       
  • Default could shutter FDA reviews

    • Free pre-print version: Loading...

      Abstract: MAY 25, 2023 3:17 PM PDT BIOCENTURY POLITICS, POLICY & LAWDEFAULT COULD SHUTTER FDA REVIEWSBY Even if a debt crisis is averted, agency’s budget is under threathttps://www.biocentury.com/article/648074/default-could-shutter-fda-reviews© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Thu, 25 May 2023 15:17:02 -070
       
  • Turning Point team quietly reforms at Avenzo, raises $196M

    • Free pre-print version: Loading...

      Abstract: MAY 25, 2023 3:02 PM PDT BIOCENTURY FINANCETURNING POINT TEAM QUIETLY REFORMS AT AVENZO, RAISES $196MBY Led by Athena Countouriotis, cancer start-up hopes to build pipeline by in-licensing ADCs, bispecifics or small moleculeshttps://www.biocentury.com/article/648077/turning-point-team-quietly-reforms-at-avenzo-raises-196m© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Thu, 25 May 2023 15:02:39 -070
       
  • May 24 Quick Takes: ElevateBio unveils $401M round, base editing deal with
           Novo

    • Free pre-print version: Loading...

      Abstract: MAY 24, 2023 6:15 PM PDT BIOCENTURY DEALSMAY 24 QUICK TAKES: ELEVATEBIO UNVEILS $401M ROUND, BASE EDITING DEAL WITH NOVOBY Plus: Phase III miss for Mirati’s sitravatinib in NSCLC and updates from CMS, Phathom, OnKure, Braeburn, Pyxis-Apexigen, IPIhttps://www.biocentury.com/article/648061/may-24-quick-takes-elevatebio-unveils-401m-round-base-editing-deal-with-novo© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Wed, 24 May 2023 18:15:09 -070
       
  • Bispecifics improve targeting of liposomal drugs; plus method to interpret
           GWAS findings and more

    • Free pre-print version: Loading...

      Abstract: MAY 24, 2023 5:34 PM PDT BIOCENTURY DISCOVERY & TRANSLATIONBISPECIFICS IMPROVE TARGETING OF LIPOSOMAL DRUGS; PLUS METHOD TO INTERPRET GWAS FINDINGS AND MOREBY BioCentury’s roundup of translational newshttps://www.biocentury.com/article/648055/bispecifics-improve-targeting-of-liposomal-drugs-plus-method-to-interpret-gwas-findings-and-more© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Wed, 24 May 2023 17:34:46 -070
       
  • Alvin Luk named CEO of HuidaGene

    • Free pre-print version: Loading...

      Abstract: MAY 24, 2023 5:30 PM PDT BIOCENTURY MANAGEMENT TRACKSALVIN LUK NAMED CEO OF HUIDAGENEBY Plus:TScan’s MacBeath now permanent CEO; chair, CMO, seed money for InProTherhttps://www.biocentury.com/article/648067/alvin-luk-named-ceo-of-huidagene© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Wed, 24 May 2023 17:30:24 -070
       
  • Sarepta’s DMD saga casts more clouds on FDA’s
           decision-making 

    • Free pre-print version: Loading...

      Abstract: MAY 24, 2023 5:27 PM PDT BIOCENTURY REGULATIONSAREPTA’S DMD SAGA CASTS MORE CLOUDS ON FDA’S DECISION-MAKING BY  A slimmer label for Sarepta’s gene therapy could have big consequenceshttps://www.biocentury.com/article/648062/sarepta-s-dmd-saga-casts-more-clouds-on-fda-s-decision-making© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Wed, 24 May 2023 17:27:07 -070
       
  • Lupus consortium could be model for joining FDA, NIH, patients and
           industry

    • Free pre-print version: Loading...

      Abstract: MAY 24, 2023 3:28 PM PDT BIOCENTURY PRODUCT DEVELOPMENTLUPUS CONSORTIUM COULD BE MODEL FOR JOINING FDA, NIH, PATIENTS AND INDUSTRYBY ARPA-H seeking ideas for collaboration with FDAhttps://www.biocentury.com/article/648014/lupus-consortium-could-be-model-for-joining-fda-nih-patients-and-industry© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Wed, 24 May 2023 15:28:45 -070
       
  • May 23 Quick Takes: VCs back cancer play Larkspur with $35.5M

    • Free pre-print version: Loading...

      Abstract: MAY 23, 2023 5:40 PM PDT BIOCENTURY FINANCEMAY 23 QUICK TAKES: VCS BACK CANCER PLAY LARKSPUR WITH $35.5MBY Plus: PTC reports vatiquinone Phase III miss, discontinuation of gene therapies and updates from Innoviva, Pfizer, Wave, Arrowhead, Icosavax and more https://www.biocentury.com/article/648043/may-23-quick-takes-vcs-back-cancer-play-larkspur-with-35-5m© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Tue, 23 May 2023 17:40:36 -070
       
  • The missing links: how to ensure omics data fulfills its promise

    • Free pre-print version: Loading...

      Abstract: MAY 23, 2023 4:48 PM PDT BIOCENTURY GUEST COMMENTARYTHE MISSING LINKS: HOW TO ENSURE OMICS DATA FULFILLS ITS PROMISEBY Generalizable frameworks for longitudinal studies and interoperable data sharing systems needed to maximize omics impacthttps://www.biocentury.com/article/647907/the-missing-links-how-to-ensure-omics-data-fulfills-its-promise© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Tue, 23 May 2023 16:48:29 -070
       
  • ReNAgade: getting RNA therapies outside the liver

    • Free pre-print version: Loading...

      Abstract: MAY 23, 2023 4:38 PM PDT BIOCENTURY EMERGING COMPANY PROFILERENAGADE: GETTING RNA THERAPIES OUTSIDE THE LIVERBY Over $300M in series A funding gives the RNA medicines company enough capital to reach the clinichttps://www.biocentury.com/article/648039/renagade-getting-rna-therapies-outside-the-liver© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Tue, 23 May 2023 16:38:41 -070
       
  • Obsidian fills CEO, CDO roles with Iovance vets

    • Free pre-print version: Loading...

      Abstract: MAY 23, 2023 4:14 PM PDT BIOCENTURY MANAGEMENT TRACKSOBSIDIAN FILLS CEO, CDO ROLES WITH IOVANCE VETSBY Plus: Jami Rubin joins Arch, and updates from Exo, Harbinger, Twist and morehttps://www.biocentury.com/article/648047/obsidian-fills-ceo-cdo-roles-with-iovance-vets© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Tue, 23 May 2023 16:14:48 -070
       
  • Most-active investors in European biotechs

    • Free pre-print version: Loading...

      Abstract: MAY 23, 2023 2:36 PM PDT BIOCENTURY DATA BYTEMOST-ACTIVE INVESTORS IN EUROPEAN BIOTECHSBY Novo tops list with 43 investments in European biotechshttps://www.biocentury.com/article/648006/most-active-investors-in-european-biotechs© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Tue, 23 May 2023 14:36:46 -070
       
  • Sizing up VectivBio’s takeout premium among '23 M&A deals

    • Free pre-print version: Loading...

      Abstract: MAY 23, 2023 2:08 PM PDT BIOCENTURY DEALSSIZING UP VECTIVBIO’S TAKEOUT PREMIUM AMONG '23 M&A DEALSBY Many companies with late-stage assets have commanded triple-digit premiumshttps://www.biocentury.com/article/648021/sizing-up-vectivbio-s-takeout-premium-among-23-m-a-deals© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Tue, 23 May 2023 14:08:45 -070
       
  • DMD gene therapies, CBER & NIH: a BioCentury podcast

    • Free pre-print version: Loading...

      Abstract: MAY 22, 2023 5:24 PM PDT BIOCENTURY PRODUCT DEVELOPMENTDMD GENE THERAPIES, CBER & NIH: A BIOCENTURY PODCASTBY The landscape for Duchenne muscular dystrophy gene therapies; plus insights from FDA’s Peter Marks and priorities for Monica Bertagnolli https://www.biocentury.com/article/648026/dmd-gene-therapies-cber-nih-a-biocentury-podcast© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Mon, 22 May 2023 17:24:24 -070
       
  • Coelho succeeds Lankry as Gamida CFO

    • Free pre-print version: Loading...

      Abstract: MAY 22, 2023 5:22 PM PDT BIOCENTURY MANAGEMENT TRACKSCOELHO SUCCEEDS LANKRY AS GAMIDA CFOBY Plus: Sullivan becomes chief strategy officer at BioAge, and updates from Athira, Ambrx and FNIHhttps://www.biocentury.com/article/648013/coelho-succeeds-lankry-as-gamida-cfo© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Mon, 22 May 2023 17:22:27 -070
       
  • May 22 Quick Takes: Ironwood building GI franchise via $1B VectivBio
           acquisition

    • Free pre-print version: Loading...

      Abstract: MAY 22, 2023 3:44 PM PDT BIOCENTURY DEALSMAY 22 QUICK TAKES: IRONWOOD BUILDING GI FRANCHISE VIA $1B VECTIVBIO ACQUISITIONBY Plus: Krystal raises $160M PIPE and updates from Avrobio-Novartis, Avidity, BMS, Hepion, Rain, Blueprint https://www.biocentury.com/article/648025/may-22-quick-takes-ironwood-building-gi-franchise-via-1b-vectivbio-acquisition© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Mon, 22 May 2023 15:44:25 -070
       
  • Ning Zhao, WuXi co-founder and philanthropist, passes away

    • Free pre-print version: Loading...

      Abstract: MAY 22, 2023 3:26 PM PDT BIOCENTURY MANAGEMENT TRACKSNING ZHAO, WUXI CO-FOUNDER AND PHILANTHROPIST, PASSES AWAYBY Scientist, executive helped shape WuXi AppTec, WuXi Biologicshttps://www.biocentury.com/article/648028/ning-zhao-wuxi-co-founder-and-philanthropist-passes-away© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Mon, 22 May 2023 15:26:24 -070
       
  • Novo’s obesity portfolio gains momentum with oral semaglutide data

    • Free pre-print version: Loading...

      Abstract: MAY 22, 2023 3:22 PM PDT BIOCENTURY DATA BYTENOVO’S OBESITY PORTFOLIO GAINS MOMENTUM WITH ORAL SEMAGLUTIDE DATABY Oral semaglutide matches Wegovy’s efficacy, but both formulations trail Lilly’s tirzepatidehttps://www.biocentury.com/article/648023/novo-s-obesity-portfolio-gains-momentum-with-oral-semaglutide-data© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Mon, 22 May 2023 15:22:48 -070
       
  • Targets for severe COVID-19; plus Alzheimer’s resistance case study
           and more

    • Free pre-print version: Loading...

      Abstract: MAY 19, 2023 4:57 PM PDT BIOCENTURY DISCOVERY & TRANSLATIONTARGETS FOR SEVERE COVID-19; PLUS ALZHEIMER’S RESISTANCE CASE STUDY AND MOREBY BioCentury’s roundup of translational newshttps://www.biocentury.com/article/648019/targets-for-severe-covid-19-plus-alzheimer-s-resistance-case-study-and-more© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Fri, 19 May 2023 16:57:22 -070
       
  • Will a gene therapy approval in DMD harm innovation'

    • Free pre-print version: Loading...

      Abstract: MAY 19, 2023 4:29 PM PDT BIOCENTURY PRODUCT DEVELOPMENTWILL A GENE THERAPY APPROVAL IN DMD HARM INNOVATION'BY A deep pipeline of gene therapy candidates follows Sarepta’s SRP-9001, meaning patients may face a tough choicehttps://www.biocentury.com/article/647978/will-a-gene-therapy-approval-in-dmd-harm-innovation© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Fri, 19 May 2023 16:29:27 -070
       
  • May 19 Quick Takes: AbbVie wins accelerated approval of bispecific for
           DLBCL

    • Free pre-print version: Loading...

      Abstract: MAY 19, 2023 3:51 PM PDT BIOCENTURY REGULATIONMAY 19 QUICK TAKES: ABBVIE WINS ACCELERATED APPROVAL OF BISPECIFIC FOR DLBCLBY Plus: Another setback for Intercept’s NASH candidate, and updates from Krystal, Modernahttps://www.biocentury.com/article/648011/may-19-quick-takes-abbvie-wins-accelerated-approval-of-bispecific-for-dlbcl© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Fri, 19 May 2023 15:51:00 -070
       
  • Second closing time for series B rounds

    • Free pre-print version: Loading...

      Abstract: MAY 19, 2023 1:19 PM PDT BIOCENTURY FINANCESECOND CLOSING TIME FOR SERIES B ROUNDSBY Series B extensions represent one third of all series B offerings this yearhttps://www.biocentury.com/article/648002/second-closing-time-for-series-b-rounds© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Fri, 19 May 2023 13:19:30 -070
       
  • Sandrock’s new Voyage

    • Free pre-print version: Loading...

      Abstract: MAY 19, 2023 7:46 AM PDT BIOCENTURY PRODUCT DEVELOPMENTSANDROCK’S NEW VOYAGEBY CNS-penetrant capsids could provide platform for Voyager revivalhttps://www.biocentury.com/article/647893/sandrock-s-new-voyage© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Fri, 19 May 2023 07:46:36 -070
       
  • In vivo CAR T cell advances showcased at ASGCT

    • Free pre-print version: Loading...

      Abstract: MAY 18, 2023 5:39 PM PDT BIOCENTURY PRODUCT DEVELOPMENTIN VIVO CAR T CELL ADVANCES SHOWCASED AT ASGCTBY Kelonia shows safety in non-human primates, while Umoja shows efficacy in solid tumors in micehttps://www.biocentury.com/article/647974/in-vivo-car-t-cell-advances-showcased-at-asgct© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Thu, 18 May 2023 17:39:26 -070
       
  • Amgen v. Sanofi ruling promotes competition within drug classes

    • Free pre-print version: Loading...

      Abstract: MAY 18, 2023 5:06 PM PDT BIOCENTURY POLITICS, POLICY & LAWAMGEN V. SANOFI RULING PROMOTES COMPETITION WITHIN DRUG CLASSESBY Supreme Court decision puts an end to antibody genus claims. It could hurt more differentiated innovationhttps://www.biocentury.com/article/647997/amgen-v-sanofi-ruling-promotes-competition-within-drug-classes© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Thu, 18 May 2023 17:06:30 -070
       
  • May 18 Quick Takes: Vaccines panel backs Pfizer RSV vaccine

    • Free pre-print version: Loading...

      Abstract: MAY 18, 2023 4:25 PM PDT BIOCENTURY REGULATIONMAY 18 QUICK TAKES: VACCINES PANEL BACKS PFIZER RSV VACCINEBY Plus: Pressure mounts on CMS over Alzheimer’s therapies, financing updates for Coherent, Myeloid, Cabaletta, RedCloud, CytoCares, and more   https://www.biocentury.com/article/647980/may-18-quick-takes-vaccines-panel-backs-pfizer-rsv-vaccine© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Thu, 18 May 2023 16:25:20 -070
       
  • Teva’s innovative growth strategy, Part Deux

    • Free pre-print version: Loading...

      Abstract: MAY 18, 2023 2:42 PM PDT BIOCENTURY PRODUCT DEVELOPMENTTEVA’S INNOVATIVE GROWTH STRATEGY, PART DEUXBY Does the pharma have the financial firepower to match its ambition'https://www.biocentury.com/article/648000/teva-s-innovative-growth-strategy-part-deux© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Thu, 18 May 2023 14:42:22 -070
       
  • Klompas steps down as Zymeworks’ COO, president

    • Free pre-print version: Loading...

      Abstract: MAY 18, 2023 12:20 PM PDT BIOCENTURY MANAGEMENT TRACKSKLOMPAS STEPS DOWN AS ZYMEWORKS’ COO, PRESIDENTBY Plus: Bloom names Colón chair, Replay hires Balakumaran as CMOhttps://www.biocentury.com/article/647996/klompas-steps-down-as-zymeworks-coo-president© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Thu, 18 May 2023 12:20:21 -070
       
  • Regulatory innovations will speed ultra-rare therapies, Marks says

    • Free pre-print version: Loading...

      Abstract: MAY 18, 2023 5:19 AM PDT BIOCENTURY POLITICS, POLICY & LAWREGULATORY INNOVATIONS WILL SPEED ULTRA-RARE THERAPIES, MARKS SAYSBY On The BioCentury Show, CBER director discusses orphan strategies, pandemic preparedness, management issues https://www.biocentury.com/article/647993/regulatory-innovations-will-speed-ultra-rare-therapies-marks-says© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Thu, 18 May 2023 05:19:23 -070
       
  • Roche’s Perettie to head cell therapy at Kite

    • Free pre-print version: Loading...

      Abstract: MAY 17, 2023 5:34 PM PDT BIOCENTURY MANAGEMENT TRACKSROCHE’S PERETTIE TO HEAD CELL THERAPY AT KITEBY Plus: Ochre appoints Forster as chairperson and updates from Women In Bio, Verismo and MIGhttps://www.biocentury.com/article/647988/roche-s-perettie-to-head-cell-therapy-at-kite© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Wed, 17 May 2023 17:34:22 -070
       
  • May 17 Quick Takes: Intercept falls on negative tone of FDA briefing docs

    • Free pre-print version: Loading...

      Abstract: MAY 17, 2023 4:42 PM PDT BIOCENTURY REGULATIONMAY 17 QUICK TAKES: INTERCEPT FALLS ON NEGATIVE TONE OF FDA BRIEFING DOCSBY Plus: Siren, Sania debut and updates from Aitia, PTC, enGene, Ardelyx, Akero and Satellos   https://www.biocentury.com/article/647983/may-17-quick-takes-intercept-falls-on-negative-tone-of-fda-briefing-docs© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Wed, 17 May 2023 16:42:26 -070
       
  • Acidifying lysosomes to treat NAFLD; Sherlock’s nucleic acid
           assay and more

    • Free pre-print version: Loading...

      Abstract: MAY 17, 2023 3:49 PM PDT BIOCENTURY DISCOVERY & TRANSLATIONACIDIFYING LYSOSOMES TO TREAT NAFLD; SHERLOCK’S NUCLEIC ACID ASSAY AND MOREBY BioCentury’s roundup of translational newshttps://www.biocentury.com/article/647985/acidifying-lysosomes-to-treat-nafld-sherlock-s-nucleic-acid-assay-and-more© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Wed, 17 May 2023 15:49:00 -070
       
  • Series A financings start to slow

    • Free pre-print version: Loading...

      Abstract: MAY 17, 2023 3:07 PM PDT BIOCENTURY DATA BYTESERIES A FINANCINGS START TO SLOWBY Fewer biotechs raised series A rounds in the first four months of 2023 than in the same period in the previous four yearshttps://www.biocentury.com/article/647943/series-a-financings-start-to-slow© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Wed, 17 May 2023 15:07:40 -070
       
  • Nido Bio: treating neurodegeneration with small molecules

    • Free pre-print version: Loading...

      Abstract: MAY 17, 2023 3:00 PM PDT BIOCENTURY EMERGING COMPANY PROFILENIDO BIO: TREATING NEURODEGENERATION WITH SMALL MOLECULESBY Debuting with $109M, 5AM Ventures-backed company developing small molecule corrector of a genetic neuromuscular diseasehttps://www.biocentury.com/article/647916/nido-bio-treating-neurodegeneration-with-small-molecules© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Wed, 17 May 2023 15:00:54 -070
       
  • FDA veteran Dunn to join Prothena’s board

    • Free pre-print version: Loading...

      Abstract: MAY 16, 2023 6:16 PM PDT BIOCENTURY MANAGEMENT TRACKSFDA VETERAN DUNN TO JOIN PROTHENA’S BOARDBY Plus: Lucera named CFO at Editas, and updates from Erasca, Sangamo, AlloVir and morehttps://www.biocentury.com/article/647958/fda-veteran-dunn-to-join-prothena-s-board© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Tue, 16 May 2023 18:16:01 -070
       
  • Data comp: RSV prophylactics for infants

    • Free pre-print version: Loading...

      Abstract: MAY 16, 2023 5:46 PM PDT BIOCENTURY DATA BYTEDATA COMP: RSV PROPHYLACTICS FOR INFANTSBY An FDA advisory committee this week will evaluate Pfizer’s Abrysvo vaccine, one of two infant RSV interventions up for FDA approval this yearhttps://www.biocentury.com/article/647967/data-comp-rsv-prophylactics-for-infants© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Tue, 16 May 2023 17:46:17 -070
       
  • Comparing Phase II NASH data from Viking and Madrigal

    • Free pre-print version: Loading...

      Abstract: MAY 16, 2023 5:43 PM PDT BIOCENTURY DATA BYTECOMPARING PHASE II NASH DATA FROM VIKING AND MADRIGALBY Viking’s VK2809 appears to reduce liver fat as well as Madrigal’s resmetirom, which went on to show efficacy in Phase III https://www.biocentury.com/article/647956/comparing-phase-ii-nash-data-from-viking-and-madrigal© 2023 BioCentury Inc. All Rights Reserved
      PubDate: Tue, 16 May 2023 17:43:42 -070
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 18.232.31.255
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-